| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Cynthia McLaughlin
Rosalio Madrigal
Rosalio Madrigal
Jenna Brashear
Jenna Brashear
| Share Statistics | BBOT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $648.1 | $252.6 | 40% |
|
| Shares Out (Mil) | 80.0 | 52.3 | 58% |
|
| Institutional Ownership | 100.0% | 92.1% | 99% |
|
| Float (Mil) | 35.7 | 40.2 | 40% |
|
| Beta | 0.22 | 0.95 | 13% |
|
| Avg Daily Volume (000s) | 280 | 455 | 50% |
|
| Price Change (52-week) |
(24.5%) | 52.9% | 28% |
|
| Growth | BBOT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (9.9%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 9 | |
| Current EPS | ($0.543) | ($2.213) | ($2.106) | |
| Month Ago EPS | ($0.543) | ($2.232) | ($2.125) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.520) | ($2.075) | ($2.048) | |
| Year/Year Chg | 3.2% | (48.6%) | (46.9%) | |
| Financials | BBOT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($154) | ($43) | 8% |
|
| EPS (TTM) | ($3.018) | ($1.600) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($130) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $26 | $5 | 65% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $5 | 20% |
|
| Enterprise Value (Q1) (Mil) | $297 | $180 | 30% |
|
| Valuation | BBOT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.74 | 2.56 | 46% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | BBOT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (54.3%) | (49.8%) | 11% |
|
| ROE | (178.9%) | (55.5%) | 5% |
|
| Liabilities to Assets | 10.9% | 30.3% | 6% |
|
| F-Score | 2 | 3 | na |
|
BridgeBio Oncology Therapeutics, Inc. did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
